Clinical Trial Update: Sitravatinib in Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of sitravatinib in metastatic breast cancer, including triple-negative breast cancer, was terminated with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Sitravatinib (sitravatinib)

Snippet

Sponsor: Xiang Zhang | Conditions: Breast Cancer Stage IV, Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-08-26